Purpose: To evaluate attitudes toward current treatments for vision correction in a clinical population of adults wearing spectacles and contact lenses (CLs).
Methods: Patients seen in the Indiana University Contact Lens and Primary Care Clinics in the spring of 2002 completed multiple-choice questionnaires evaluating their current device for vision, comfort, convenience, health and safety, cost, and overall satisfaction. They also rated their interest in and the convenience and health and safety of 30-day continuous wear (CW), 7-day extended wear (EW), modern orthokeratology, and LASIK and were given a forced choice on their preferred method of vision correction.
Results: Three hundred forty-nine CL and 177 primary care patients completed questionnaires. Subjects reported high satisfaction with their current treatment. Seventy percent of glasses wearers were neutral or not interested in CLs or LASIK. CL patients were interested or very interested in orthokeratology (70%) followed by LASIK (65%), 7-day EW (51%), and 30-day CW (44%). Age and sex were the most significant factors that influenced wearing practices and attitudes, with males (especially young) indicating significantly higher use of EW than females (P = 0.0005, chi(2)). Males were also more interested in 7-day EW (P = 0.011) and 30-day CW (P = 0.001) and rated their health and safety higher (P = 0.045 and P = 0.003, respectively).
Conclusions: In the spring of 2002, many of these patients remained cautious about the health and safety of 7-day EW and 30-day CW CLs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.icl.0000138719.59214.b7 | DOI Listing |
J Rehabil Med
January 2025
Clinic of Medical Rehabilitation, Medical University of Lodz, Lodz, Poland.
Objective: The aim of this study is to evaluate the effectiveness of immersive technologies in the rehabilitation of patients with non-specific neck pain and identify any potential side effects associated with their use.
Design: Systematic review.
Subjects/patients: Individuals with non-specific neck pain.
Curr Drug Targets
January 2025
Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, India.
Acne vulgaris is the 8th most commonly prevailing skin disorder worldwide. Its pervasiveness has been predominant in juveniles, especially males, during adolescence and in females during adulthood. The lifestyle and nutrition adopted have been significantly reported to impact the occurrence and frequency of acne.
View Article and Find Full Text PDFIntroduction: Chronic ischemic heart failure is a major global health issue despite advancements in therapy. Stem cell (SC) therapy has emerged as a potential treatment, but its effectiveness remains uncertain. This study aimed to systematically review and meta-analyze the current evidence on SC therapy's efficacy.
View Article and Find Full Text PDFCardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFHypertension
January 2025
Department of Medicine, Unit of Internal Medicine B, University of Verona School of Medicine, Azienda Ospedaliera Universitaria Integrata Verona, Policlinico G.B. Rossi, Italy.
Background: Hypertension is a major global health issue. Aldosterone synthase inhibitors (ASIs) have emerged as a promising therapeutic strategy for blood pressure control.
Methods: A thorough search of the MEDLINE and Embase databases up to March 30, 2024, identified randomized trials comparing ASIs with a placebo for hypertension treatment.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!